CELLO - CLiRpath® Excimer Laser System to Enlarge Lumen Openings

Inclusion Criteria

General Inclusion Criteria

• Peripheral vascular disease Rutherford Classification 1, 2, or 3;
• Eligible for revascularization of native vessel (PTA or bypass);
• Willing and able to comply with the specified evaluations during hospitalization and all required follow-up examinations;
• Written informed consent given before execution of study procedures; and
• Age > 18 and ≤ 85 years.

Angiographic Inclusion Criteria

• Reference vessel diameter >/= 4.0 mm and ≤ 7.0 mm as determined by physician visual angiographic assessment of the most normally appearing vessel segment within 10 mm proximal AND 10 mm distal to the target segment.
• Stenosis within the SFA and/or popliteal artery above the knee of >/= 70% and /= 1.0 cm and ≤ 15.0 cm as determined by visual angiographic assessment at the time of the procedure, separate multiple lesions can be combined as two separate treatment areas as long as the sum total of all lesion lengths and/or treatment areas does not exceed 1.0 cm to 15.0 cm.
• Patency ( 2.0 mg/dL;
• Uncompensated congestive heart failure;
• Current enrollment in any investigational study wherein patient participation has not been completed;
• Prior enrollment in this study;
• Suspected or confirmed pregnancy;
• Any patient, who in the opinion of the investigator, would not be a good candidate for enrollment;
• Myocardial infarction within 60 days; and
• CVA/TIA within 60 days. Angiographic Exclusion Criteria

1.

• Subintimal guidewire placement following pilot channel creation through a stenosis or occlusion with any excimer laser catheter, as visualized with IVUS;
• Calcification likely to prevent the passage of the excimer laser catheter or CLiRpath® Photoablation Atherectomy system;
• Ipsilateral and/or contralateral iliac stenosis >/= 50% DS that is not treated prior to enrollment in this study;
• Ipsilateral and/or contralateral iliac treatment of a stenosis prior to enrollment with final residual stenosis >/= 30%, as determined in at least two (2) orthogonal views and documented by angiography;
• Iliac treatment prior to enrollment where a perforation occurred requiring a covered stent, blood transfusion, or surgery for treatment of the perforation;
• Identification of any lesion above the knee and/or below the knee in the treated leg (ipsilateral) that will require preplanned or predicted treatment within six (6) months after enrollment and prior to the completion of the six (6) month follow-up, including the iliac artery, the common femoral artery, the peroneal, anterior tibial, or posterior tibial arteries, or any area from the iliacs to the foot outside of the treatment area;
• Lesions proximal and distal to the treatment site that are >/= 50% DS at time of enrollment;
• Contralateral leg disease that requires treatment within the next 30 days and prior to completion of the 30 day follow-up;
• Cardiovascular surgical or cardiovascular interventional procedures (including, but not limited to, aortic, renal, cardiac, carotid, femoro-popliteal, and below the knee) within 30 days prior to enrollment in this study;
• Planned or predicted cardiovascular surgical or interventional procedures outside of the ipsilateral leg (including, but not limited to aortic, renal, cardiac, carotid, contralateral femoro-popliteal, and contralateral below the knee) within 30 days after entry into this study, and prior to completion of the 30-day follow-up; and
• Perforation or dissection of grade "C" or greater seen during or after the creation of the pilot channel.